Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, r-hirudin, and Ro 43-8857 GPIIb/IIIa antagonist
Animal model study published in Thrombosis and Haemostasis (1995)
Abstract
Inhibition of arterial thrombus formation by ancrod, a fibrinogen depleting agent isolated from a snake venom, r-hirudin, an inhibitor of thrombin-mediated fibrinogen cleavage, or the glycoprotein (GP)IIB/IIIa-receptor antagonist Ro 43-8857 interfering with fibrinogen binding to platelets, was evaluated in two canine models. As a marker of platelet-dependent thrombus formation, cyclic blood flow reductions (CFR) were induced in the left coronary artery (LAD) of mongrel dogs by mechanical injury of the endothelium combined with critical stenosis. In the second model CFRs were induced by thrombolysis of a copper coil-induced thrombus in the carotid artery. Blood flow rate during the reocclusion phase was used as an additional parameter of efficacy. The frequency of CFRs used a indicator of platelet aggregation and adhesion was significantly diminished by all treatments in both the carotid artery- and the LAD-model. In the LAD-model, following ancrod treatment, CFRs were correlated with plasma fibrinogen concentrations. Carotid artery blood flow after reperfusion, used as indicator of occlusive thrombus formation, rapidly declined to zero in the control group but remained at a high level after treatment with ancrod or r-hirudin. Ro 43-8857 at the selected dose improved flow rate only to a minor degree but prolonged the bleeding time from a mean value of 87.2 +/- 10.9 s (n = 24) to values > 300 s in 50% of the animals. Our results indicate that CFRs as indicator of platelet aggregation and adhesion are inhibited by either treatments. Blood flow as indicator of occlusive thrombus formation, however, is effectively improved by ancrod and r-hirudin only. Inhibition of fibrinogen binding to platelet GPIIb/IIIa receptors alone was found to be less potent antithrombotic principle in this model.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Two canine models of arterial thrombus formation: r-hirudin and ancrod (fibrinogen-depleter from snake venom) effectively maintained blood flow after carotid reperfusion, while Ro 43-8857 GPIIb/IIIa antagonist only modestly improved flow at the cost of greatly prolonged bleeding time.
Why This Matters for Hirudotherapy
This comparative canine study evaluated three antithrombotic agents — ancrod, r-hirudin, and the GPIIb/IIIa antagonist Ro 43-8857 — across two arterial thrombosis models involving cyclic blood flow reductions (CFRs) in the LAD coronary and carotid arteries. All three agents significantly reduced CFRs in both models. However, only ancrod and r-hirudin effectively maintained post-reperfusion carotid blood flow; the GPIIb-IIIa antagonist at the selected dose showed only minor flow improvement but prolonged bleeding time (>300 s in 50% of animals). The abstract concludes that blood flow as an indicator of occlusive thrombus formation is effectively improved by ancrod and r-hirudin only. Relevance to ASH's domain is indirect: the study evaluates recombinant hirudin but does not mention leeches or hirudotherapy. The study is limited by its animal model.
Citation
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026